BriaCell Therapeutics (TSE:BCT) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BriaCell Therapeutics has announced promising results from their Phase 2 clinical trial, showcasing improved overall survival rates for metastatic breast cancer patients treated with their Bria-IMT™ combination therapy. The therapy demonstrated significant clinical benefits across various breast cancer subtypes, suggesting potential advancements in treatment options for this challenging condition.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.